Content last updated on: May 29, 2017


2017 May 29

Since the beginning of 2017 canakinumab has been approved for the treatment of HIDS, TRAPS and for patients with FMF in whom colchicine is insufficiently effective. This is good news for patients with these diseases that now use daily anakinra or other treatments. If you think you could use canakinumab instead of your current drug, please talk to you treating physician about this.